Table 2.
Genotype‐predicted warfarin responder categories
| CYP2C9 genotype | |||||||
|---|---|---|---|---|---|---|---|
| *1/*1 | *1/*2 | *1/*3 | *2/*2 | *2/*3 | *3/*3 | ||
| VKORC1 genotype | G/G | Normal | Normal | Sensitive | Sensitive | Sensitive | Highly sensitive |
| G/A | Normal | Sensitive | Sensitive | Sensitive | Highly sensitive | Highly sensitive | |
| A/A | Sensitive | Sensitive | Highly sensitive | Highly sensitive | Highly sensitive | Highly sensitive | |
Genotype‐predicted warfarin responder groups were determined by cytochrome P450 (CYP)2C9 *1, *2, and *3 and VKORC1 c. ‐1639 G>A genotype. Our study cohort did not contain any participants who were genotyped as *3/*3 for CYP2C9. VKORC, vitamin K epoxide reductase complex.